Autolus Therapeutics plc ADR (NASDAQ: AUTL)’s stock price has gone decline by -4.55 in comparison to its previous close of 1.98, however, the company has experienced a -8.70% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-06 that LONDON, March 06, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company’s financial results and provide a general business update.
Is It Worth Investing in Autolus Therapeutics plc ADR (NASDAQ: AUTL) Right Now?
The 36-month beta value for AUTL is also noteworthy at 1.93. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AUTL is 240.31M, and at present, short sellers hold a 3.79% of that float. The average trading volume of AUTL on March 14, 2025 was 1.37M shares.
AUTL’s Market Performance
AUTL’s stock has seen a -8.70% decrease for the week, with a -1.05% drop in the past month and a -35.93% fall in the past quarter. The volatility ratio for the week is 6.49%, and the volatility levels for the past 30 days are at 6.15% for Autolus Therapeutics plc ADR. The simple moving average for the past 20 days is -1.43% for AUTL’s stock, with a -43.51% simple moving average for the past 200 days.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Goldman repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Goldman is $7.60 based on the research report published on November 18, 2024 of the previous year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $13. The rating they have provided for AUTL stocks is “Buy” according to the report published on November 15th, 2024.
Deutsche Bank gave a rating of “Buy” to AUTL, setting the target price at $10 in the report published on November 09th of the previous year.
AUTL Trading at -10.63% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.47% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 6.49%, as shares sank -3.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.37% lower at present.
During the last 5 trading sessions, AUTL fell by -8.70%, which changed the moving average for the period of 200-days by -51.16% in comparison to the 20-day moving average, which settled at $1.9175. In addition, Autolus Therapeutics plc ADR saw -19.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUTL starting from Martin Pule, who proposed sale 698,741 shares at the price of $4.23 back on Sep 16 ’24. After this action, Martin Pule now owns shares of Autolus Therapeutics plc ADR, valued at $2,955,674 using the latest closing price.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -17.4 for the present operating margin
- 0.52 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -22.77. The total capital return value is set at -0.27. Equity return is now at value -82.20, with -43.81 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.7. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -2.94.
Currently, EBITDA for the company is -156.77 million with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of -8.59. The receivables turnover for the company is 11.95for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.64.
Conclusion
In summary, Autolus Therapeutics plc ADR (AUTL) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
